Information Library
Results for: White Papers - The New Health
To learn more about Quintiles’ services, you may broaden or narrow your search by selecting the topics at left.
- Sort by:
- Recently Added
- Title
-
FSPs: Ranging from Tactical to Strategic Models
January 4, 2012
Biopharma companies can choose from a range of outsourcing models as they seek to respond effectively to the ever-changing conditions in the New Health. -
Strategic Alliances
December 5, 2011
Strategic alliances with specialized external partners allow companies to increase agility and the efficiency of processes, variablize resources and raise the number of promising drug candidates in their pipeline. -
An Integrated Approach to Biosimilar Development & Commercialization
September 29, 2011
As the market for biosimilar products continues to grow, many biopharmaceutical companies trying to enter the space are struggling to overcome the unique challenges that developing such products presents. -
Partnering to Maximize Rewards in Pharmerging Markets
September 15, 2011
In the past few years so-called “pharmerging” markets have been heralded as the hottest growth area for biopharmaceutical drugs. With large populations, growing disposable income and unmet medical needs, these markets have seen doubledigit growth rates in pharmaceutical spending. -
The New Health
August 23, 2011
In 2010, Quintiles advanced the concept of the New Health, our perspective on the fast-morphing biopharma landscape, where the rules are changing on all fronts. -
Methods Matter
July 18, 2011
As healthcare decision making becomes more complex, stakeholders are demanding real-world evidence tailored to their own individual needs. -
The New Health Report 2011
May 24, 2011
Download a PDF of the full 2011 New Health Report. -
The New Health Alliance
January 10, 2011
Biopharmaceutical companies must explore alternative strategic alliances that meet the needs of the New Health and produce medicines that demonstrate value to the entire constellation of stakeholders. -
The New Health
April 22, 2010
Quintiles examines the complex challenges and opportunities facing the biopharmaceutical industry and how companies must manage risk, demonstrate greater value and improve patient outcomes. -
New Voices, New Opportunities
February 19, 2010
Biopharmaceutical companies must learn to navigate the increasingly tricky waters of commercializing products by adjusting to the needs of a new set of stakeholders.
Page 1 of 1 (10 results)
